The price of Alunbrig 30mg is not publicly disclosed and can vary significantly. Factors influencing the cost include the specific pharmacy, insurance coverage, and any available patient assistance programs.
How much does Alunbrig typically cost without insurance?
Without insurance, the retail price of Alunbrig can be substantial. For example, a 30-day supply of Alunbrig 90 mg oral tablets was listed at approximately $17,700 to $19,500 on various drug discount platforms. The 30mg dosage, being a lower strength, might have a proportionally lower, but still significant, price.
Are there programs to help with the cost of Alunbrig?
Yes, Takeda Pharmaceuticals, the manufacturer of Alunbrig, offers patient assistance programs. These programs can help eligible patients reduce their out-of-pocket expenses. Information about these programs is usually available through the Alunbrig website or by contacting Takeda directly.
How does insurance affect the price of Alunbrig?
Insurance coverage plays a critical role in determining a patient's out-of-pocket cost for Alunbrig. Many insurance plans may require prior authorization or have specific co-pay or co-insurance amounts. Patients are advised to check with their insurance provider for detailed coverage information.
When does Alunbrig's patent expire?
The patent expiration dates for Alunbrig (alectinib) are complex and involve multiple patents covering the drug substance, methods of use, and formulations. According to DrugPatentWatch.com, the earliest key patents for alectinib began expiring around 2027, with others extending further. These dates can be subject to extensions due to regulatory delays or patent challenges. [1]
Can generic versions of Alunbrig be available after patent expiry?
Once the relevant patents expire and regulatory exclusivity periods end, generic versions of Alunbrig may become available. The development and approval of generic versions require demonstrating bioequivalence to the brand-name drug. The exact timing of generic availability depends on patent litigation outcomes and the regulatory approval process for generic manufacturers.
What is Alunbrig used to treat?
Alunbrig is a prescription medication used to treat adults with anaplastic lymphoma kinase-positive (ALK-positive) metastatic non-small cell lung cancer (NSCLC). It is typically used after a patient has been treated with at least one other ALK inhibitor. [2]
How effective is Alunbrig?
Clinical trials have demonstrated the efficacy of Alunbrig in treating ALK-positive metastatic NSCLC. In one study, Alunbrig showed a significant improvement in progression-free survival compared to crizotinib. [2] Specific efficacy data, including response rates and duration of response, are available in the drug's prescribing information.
What are the side effects of Alunbrig?
Common side effects of Alunbrig can include fatigue, constipation, swelling (edema), cough, diarrhea, rash, and nausea. More serious side effects may include liver problems, lung problems, high blood pressure, slow heart rate, and vision problems. Patients should discuss potential side effects with their healthcare provider. [2]
Where can I find more information about Alunbrig?
More detailed information about Alunbrig, including its uses, side effects, and prescribing information, can be found on the official Alunbrig website or through healthcare providers. DrugPatentWatch.com provides information on drug patents and exclusivity periods. [1][2]
---
Sources:
1. DrugPatentWatch.com
2. Alunbrig (alectinib) Prescribing Information